| scholarly article | Q13442814 |
| P356 | DOI | 10.5732/CJC.012.10248 |
| P8608 | Fatcat ID | release_k2oppnaex5bjzo63ljrjb7t37m |
| P932 | PMC publication ID | 3845554 |
| P698 | PubMed publication ID | 23489587 |
| P5875 | ResearchGate publication ID | 236045596 |
| P2093 | author name string | Cong Chen | |
| Robert A Beckman | |||
| P2860 | cites work | Integrating predictive biomarkers and classifiers into oncology clinical development programmes | Q37940788 |
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Evaluation of early efficacy endpoints for proof-of-concept trials | Q47912286 | ||
| The future of drug development: advancing clinical trial design. | Q51786270 | ||
| Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. | Q54220825 | ||
| Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? | Q79843510 | ||
| Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients | Q81460457 | ||
| EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 | ||
| One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens | Q27323289 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Sources of bias in specimens for research about molecular markers for cancer | Q33628822 | ||
| Randomized clinical trials with biomarkers: design issues | Q34024227 | ||
| Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. | Q34461037 | ||
| Cancer biomarkers--an invitation to the table | Q34530963 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| Genetic instability in cancer: theory and experiment | Q36206964 | ||
| Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 | ||
| Cancers exhibit a mutator phenotype: clinical implications | Q37165106 | ||
| The use of genomics in clinical trial design | Q37284262 | ||
| Efficiency of carcinogenesis: is the mutator phenotype inevitable? | Q37799101 | ||
| P433 | issue | 5 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 233-241 | |
| P577 | publication date | 2013-03-15 | |
| P1433 | published in | Chinese Journal of Cancer | Q15760211 |
| P1476 | title | New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs | |
| P478 | volume | 32 |
Search more.